In the article titled “Anticoagulation Management in Temporary Mechanical Circulatory Support Devices,”¹ published July 21, 2023, minor corrections to the final text should have been incorporated.

Introduction, sentence 5

The TandemHeart manufacturer was identified as LivaNova, and this has now been corrected to CardiacAssist, Inc.

Current Recommendations, Extracorporeal Membrane Oxygenation, column 2

Original

However, viscoelastic assays need to be studied further before they can be recommended for widespread use in the cardiac critical care unit with UFH in patients receiving ECMO. Existing studies have shown lower rates of mortality, transfusions, thrombosis, bleeding, and cost; however, the Extracorporeal Life Support Organization states that large and prospective randomized trials are needed before recommending bivalirudin as the primary anticoagulant.^6,8-10 A summary of recommendations can be found in Table I.

Correction

However, viscoelastic assays need to be studied further before they can be recommended for widespread use in monitoring UFH in patients receiving ECMO. Multiple studies have been published comparing the use of bivalirudin with UFH in patients receiving ECMO, and these studies have shown lower rates of mortality, transfusions, thrombosis, bleeding, and cost. The Extracorporeal Life Support Organization states, however, that large and prospective randomized trials are needed before it can recommend bivalirudin as the primary anticoagulant.^6,8-10 A summary of recommendations can be found in Table I.

The online article and PDF have been corrected.